PLUS1
Best deals to access real time data! |
|
SMALL CAP PRO
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
SMALL CAP BASIC
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last: $ 0.79 ◊ 0.00 (0.00%) | |
| Company Name | Stock Ticker Symbol | Market | Type | ISIN |
|---|---|---|---|---|
| Cannabics Pharmaceuticals Inc. (QB) | CNBX | Other OTC | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| +0.016 | +2.08% | 0.787 | 0.795 | 0.78 | 0.795 | 0.771 | 16:01:04 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.78 | 0.787 | 0.007 | 0.89% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 402 | 893,320 | $ 0.7864 | $ 702.47k | 390.14k | 0.60 - 2.99 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:05:55 | formt | 4,740 | $0.79 | USD |
Cannabics Pharmaceuticals Inc. (QB) Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 95.9M | 121.85M | $ -1.93M | - | -49.59 | 28.58M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Cannabics Pharmaceuticals Inc. (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 9/12/2018 | 09:11 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) |
| 8/21/2018 | 13:37 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) |
| 8/14/2018 | 13:02 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 7/16/2018 | 08:08 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 6/01/2018 | 16:33 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) |
| 5/31/2018 | 16:36 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) |
| 5/02/2018 | 09:38 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CNBX Price Data
| Period † | Open | High | Low | VWAP | Min Vol | Max Vol | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|---|---|
| 1 Week | 0 | 0.795 | 0 | 0.0000 | 0 | 893k | 0 | - | - |
| 1 Month | 0 | 0.795 | 0 | 0.0000 | 0 | 893k | 0 | - | - |
| 3 Months | 0 | 0.795 | 0 | 0.0000 | 0 | 893k | 0 | - | - |
| 6 Months | 0 | 0.795 | 0 | 0.0000 | 0 | 893k | 0 | - | - |
| 1 Year | 0 | 0.795 | 0 | 0.0000 | 0 | 893k | 0 | - | - |
| 3 Years | 0 | 0.795 | 0 | 0.0000 | 0 | 893k | 0 | - | - |
| 5 Years | 0 | 0.795 | 0 | 0.0000 | 0 | 893k | 0 | - | - |
Cannabics Pharmaceuticals Inc. (QB) Description
| Cannabics Pharmaceuticals Inc. (CNBX), is dedicated to the development of personalized diagnostic tools to provide supportive data for practitioners and patients regarding cannabinoid based cancer therapy. The Company's R&D is based in Israel, where it is fully licensed by the Ministry of Health and involves both scientific and current medical clinical studies which are registered with the US NIH. Cannabics is now creating tailored therapies for cancer patients, utilizing advanced Liquid Biopsy and HTS technology along with personalized bioinformatics tools. Cannabics' research is devoted to the discovery of cannabinoid compounds targeted to specific cancers based on the confluence of cutting edge technologies and personalized bioinformatic markers. |
